SORAYA Trial: Antibody-Drug Conjugate Produces Remissions in One-Third of Patients With Drug-Resistant Ovarian Cancer

March 22, 2022 10:22 am

by the ASCO Post Staff

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel antibody-drug conjugate therapy produced a substantially better response than standard treatments, investigators from Dana-Farber Cancer Institute reported at the … Read more

Intraperitoneal Carboplatin Plus Paclitaxel Improves PFS in Ovarian Cancer, Yet OS Results Remain Unchanged Vs IV Chemo

March 20, 2022 10:18 am

by Gina Mauro

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.

The use

Read more

Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer

March 20, 2022 9:55 am

by Hayley Virgil

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses

Read more

Ovarian Cancer Patients in PARP Inhibitor Trials Don’t Reflect Real-World Population

February 25, 2022 11:33 am

by Jonathan Goodman, MPhil

Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.

Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more

New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer

February 14, 2022 10:17 am

by Anne Doerr

A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more

Paclitaxel Plus Carboplatin Is Reportedly Non-Inferior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma

January 13, 2022 8:49 am

by Ariana Pelosci

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A combination regimen of paclitaxel

Read more

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7, 2022 11:18 am

by Kristi Rosa

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced

Read more

AGO Score Identifies Ovarian Cancer Patients Likely to Benefit from Cytoreductive Surgery

December 6, 2021 2:29 pm

by Sucharita Mistry, PhD

Cytoreductive surgery followed by chemotherapy can prolong overall survival (OS), compared with chemotherapy alone, in certain patients with relapsed ovarian cancer, according to results from the DESKTOP III trial published in the New England Journal of Read more

Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer

November 30, 2021 12:10 pm

by Nichole Tucker

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant

Read more

Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer

November 17, 2021 10:25 am

By Courtney Marabella

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.

The addition of a short-term,

Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

Patient With Cancer Answers Common Questions and Dispels Myths About Clinical Trials

October 20, 2021 12:00 am

by Kelly Irvin

The number one reason to participate in a clinical trial is because someone has to do it so new drugs can be developed to treat and even cure cancer. All of the drugs we have now were Read more

Ovarian Cancerx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer

September 23, 2021 9:19 am

LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the … Read more

Drug combination shows promise in treatment-resistant advanced ovarian cancer

September 19, 2021 3:59 pm

A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.

The combination of drugs – which both work by blocking signals cancer … Read more

Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer

September 17, 2021 4:47 pm

In the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among … Read more

Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer

September 17, 2021 4:10 pm

— Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed

Patients with relapsed platinum-sensitive ovarian cancer had significant improvement in progression-free survival (PFS) when retreated with the PARP inhibitor olaparib … Read more

Nivolumab vs Gemcitabine or Pegylated Liposomal Doxorubicin: What Regimen Improves Survival in Platinum-Resistant Ovarian Cancer?

September 15, 2021 10:44 am

By Matthew Stenger

In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial … Read more

Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist

August 5, 2021 3:51 pm

By Alan P. Lyss, MD

The COVID-19 pandemic prompted changes to standard practices for cancer clinical trials, and thought leaders have recommended continuing — and improving upon — those new practices.

These recommendations, from members of the American Association for … Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

HIPEC/Carboplatin Does Not Show Significant Results in Ovarian Cancer

July 14, 2021 3:37 pm

By Ariana Pelosci

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more